Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

LGND 50.81 +0.57 (1.13%)
price chart
Why Lemelson Capital Is Short On Ligand Pharmaceuticals
Rev. Emmanuel Lemelson is the Chief Investment Officer of Lemelson Capital Management, and investment firm that is short in Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Lemelson recently joined Benzinga's #PreMarket Prep to talk about why he thinks ...
Related articles »  
Ligand Pharmaceuticals Inc. (LGND), Inovio Pharmaceuticals Inc (INO), & Tejon ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Inovio Pharmaceuticals Inc (NASDAQ:INO) are two stocks from the pharma space that have recently seen insiders buying shares in large quantities.
Ligand Pharmaceuticals Inc. (LGND) Insider Dumps 11000 Shares  Tech Insider
Ligand Pharmaceuticals Inc. (LGND) Releases FY14 Earnings Guidance  Watch List News (press release)
Related articles »  
Ligand Pharmaceuticals Inc. Shares Gain On Q3 Pre-Announcement
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) ticked up Wednesday after the company said third-quarter results will be better than expected.
Ligand Pharmaceuticals Inc. (LGND) Issues FY14 Earnings Guidance  sleekmoney
Related articles »  
Ligand Pharmaceuticals Inc. (LGND) Insider Raises Profile By Over 20000 Shares
Ligand Pharmaceuticals Inc.(NASDAQ:LGND) saw an insider lower his exposure to the company today. The Director Jason Aryeh acquired 20,300 shares of common stock at prices ranging from $6.82 to $17.88 per share.
Ligand Pharmaceuticals Receives "Hold" Rating from Cantor ...  sleekmoney
Insider Trade Report For Ligand Pharmaceuticals  Markets Insider
Related articles »  
Commit To Purchase Ligand Pharmaceuticals At $40, Earn 21.8% Annualized ...
Investors considering a purchase of Ligand Pharmaceuticals Inc (Symbol: LGND) shares, but cautious about paying the going market price of $47.64/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Investor's Alert - Ligand Pharmaceuticals Inc. (LGND), Digital Ally, Inc ...  Techsonian (press release)
Related articles »  
Cantor Fitzgerald Reaffirms "Hold" Rating for Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals Inc. logo Ligand Pharmaceuticals (NASDAQ:LGND)'s stock had its �hold� rating reiterated by Cantor Fitzgerald in a research note issued on Thursday.
Ligand Earns Milestone Payment Triggered by EU Approval of Merck's ...  MarketWatch
Related articles »  
Ligand Pharmaceuticals Upgraded by Zacks to "Outperform" (LGND)
Ligand Pharmaceuticals Inc. logo Ligand Pharmaceuticals (NASDAQ:LGND) was upgraded by Zacks from a �neutral� rating to an �outperform� rating in a report released on Tuesday.
Ligand Pharmaceuticals Upgraded at Zacks (LGND)  Intercooler
Insiders Now Seeing Red With LGND At New 52-Week Low  NASDAQ
Related articles »  
Biotech Insider Buying: Arrowhead Research Corp. (NASDAQ:ARWR), Ligand ...
Following the transaction, the director now directly owns 49,286 shares in the company, valued at approximately $2,251,384.
Related articles »  
Pharma Sector Summary: AMAG Pharma, Sagent Pharma, Infinity Pharma ...
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) : Announced the launch of Ketorolac Tromethamine Injection, USP, a nonsteroidal anti-inflammatory agent, in three preservative-free glass vials.
Related articles »  
Worst Year-To-Date Performers: Freeport-McMoRan Inc (NYSE:FCX), Ligand ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has booked the year to date performance of -7.34% while its market capitalization stands at $ 1.06B.